NCT03708822View on ClinicalTrials.gov

Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 15, 2018

Primary Completion Date

July 20, 2022

Study Completion Date

June 30, 2024

Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG

Docetaxel and Cisplatin and Nimotuzumab

Intravenous nimotuzumab (200 mg on days 1, 8, and 15) ; Intravenous docetaxel (75 mg/m2 on day 1) ; Intravenous cisplatin (75 mg/m2 on day 1) ;

Trial Locations (1)

51000

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University,, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT03708822 - Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma | Biotech Hunter | Biotech Hunter